MORRISVILLE, N.C. , May 21, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today announced that the Company is scheduled to
MORRISVILLE, N.C. , May 09, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Tara Fitzgerald , President, Clinical Development Services, and Kari L. Delahunty , Senior Vice President, Corporate Strategy,
Highlights GAAP revenue of $1.12 billion for the three months ended March 31, 2019. Net new business awards of $5.52 billion for the trailing twelve months (TTM) ended March 31, 2019, representing a TTM book-to-bill ratio of 1.24x. Clinical Solutions segment net new business awards of $4.19 billion
Award Recognizes Company’s Vaccine Expertise, Spanning End-to-End Clinical and Commercial Solutions MORRISVILLE, N.C. , April 22, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has been named the Best
MORRISVILLE, N.C. , April 18, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it won the first ever Association for Clinical Research Professionals (ACRP) Challenge for Sponsors and CROs . The competition,
MORRISVILLE, N.C. , April 10, 2019 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), will release its first quarter 2019 financial
Highlights GAAP total revenue of $1.15 billion and $4.39 billion for the fourth quarter and year ended December 31, 2018, respectively. Adjusted service revenue under ASC 606 of $1.15 billion and $4.40 billion for the fourth quarter and year ended December 31, 2018, respectively.
MORRISVILLE, N.C. , March 14, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), will release its fourth quarter and year end 2018
MORRISVILLE, N.C. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH) announced today that it has delayed its previously announced earnings release and conference call to allow additional time to complete its Form 10-K for the year ended December 31, 2018 .
MORRISVILLE, N.C. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), will release its fourth quarter and year end 2018
MORRISVILLE, N.C. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Paul Colvin as President, Clinical Solutions. Colvin joins Syneos Health from Pharmaceutical Product
Company to Release New Survey Findings from C-Suite Leaders on Commercial Spend and Planning and Essentials for a Successful Launch MORRISVILLE, N.C. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will share new
